
Midday top 10 gainers: CERE +73% . CTB +41% . SGOC +28% . ULTA +17% . GPRC +14% . SE +10% . UQM +9% . AFFY +9% . AMED +9% . HMA +9% . Midday top 10 Losers: IQNT -17% . KNDI -17% . CLSN -14% . TELK -12% . RLOG -12
13% . CLIR +13% . TPLM +12% . RVLT +13% . KNDI +12% . Midday top 10 Losers: DVAX -35% . OSH -18% . ECTE -16% . AFFY -14% . AEPI -14% . OMX -12% . SHI -12% . PLM -11% . GNRC -11% . CBAK -11% . Post your comment!
JKS +11% . ROSG +11% . THO +10% . ECTY +10% . KFS +9% . Midday top 10 Losers: FSGI -56% . TIVO -17% . USM -17% . IRM -16% . ZQK -12% . JRCC -11% . LQDT -11% . AFFY -10% . CBPO -10% . TRUE -8% . Post your comment!
By Brian L. Wilson : In February 2013, Affymax (NASDAQ: AFFY ) made headlines after a nationwide voluntary recall ..... 7% at the time of writing. Things worsened for Affymax shareholders when the company announced a month later
Shares of Affymax ( AFFY +31.5% ) soar today on the back of what appears to be a massive short squeeze . The most recent data on the stock has short
Premarket gainers: OVTI +21% . NBG +19% . AFFY +8% . CLSN +8% . KKD +7% . ETRM +6% . LEDS +6% . GES +5% . Losers: PANW -13% . PLM -12% . MHGC -7% . NMR -6% . Post your comment!
By PropThink : By Jake King Shares of Keryx Biopharmaceuticals ( KERX ) continue to trade within a tight range, but with several catalyzing events approaching, we believe the stock is ready to break out. In particular, clinical evidence for a second, larger indication for Keryx's late-stage ...
possible reversal, you will see that biotech company Affymax ( AFFY ) stock did in fact bounce in share price recently ..... traders like me may want to continue to hold. In short, Affymax is still alive. Some speculative traders who entered
Premarket gainers: CHCI +41% . DVR +25% . CLNT +14% . VIPS +13% . EJ +11% . AFFY +9% . CHLN +9% . SPWR +8% . AVEO +5% . Losers: XONE -10% . RMTI -8% . WMC -5% . 2 comments!
Epogen and Aranesp to see stronger sales in the near term, particularly over the next two years, following the withdrawal of Affymax 's Omontys from the market. Sales growth from Prolia/Xgeva, Nplate, and Amgen's late-stage pipeline should largely